Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Phase I/II Clinical Trial Results for Lupus Patients

May 19, 2011 5:03 am | News | Comments

Neovacs published the initial results of a phase I/II study with IFN?-Kinoid in lupus patients that highlights the safety, immunogenicity, and the pharmacodynamics of the therapy, according to a report by Neovacs.


MS Patients Show Relapse Rate Reduction in Coptimize Study

May 19, 2011 4:58 am | News | Comments

Teva Pharmaceutical reported preliminary data from two studies, Coptimize and QualiCop.


Epstein-Barr Could Be MS Risk Factor

May 18, 2011 11:54 am | News | Comments

The Epstein-Barr virus, belonging to the herpesviruses family, which also includes the herpes simplex virus and the cytomegalovirus, is one of the environmental factors that might cause multiple sclerosis.


Researchers Discover Gene Linked to Aging Hearts

May 18, 2011 11:50 am | News | Comments

Researchers have identified a novel gene in the nucleus of muscle and brain cells that affects heart development and the aging process. Their investigation brings the promise of new treatments for an old, failing heart.


Avantor Successfully Completes Rx-360 Audit

May 18, 2011 11:47 am | News | Comments

Avantor Performance Materials has completed the first supply chain security audit by Rx-360, a consortium of pharmaceutical and biotechnology companies and suppliers dedicated to improving pharmaceutical supply chain security.


Clinipace Acquires PFC Pharma Focus

May 18, 2011 11:38 am | News | Comments

Clinipace Worldwide, a global digital clinical research organization, and Swiss-based PFC Pharma Focus announced a merger agreement under which Clinipace Worldwide has acquired all outstanding shares of privately-held PFC and its subsidiaries.


Titration Monitoring

May 18, 2011 11:30 am | Product Releases | Comments

METTLER TOLEDO has introduced LevelSens; the new titration, density, and refractive index accessory for solution monitoring to increase security in the laboratory.


Freezer Box

May 18, 2011 11:26 am | Product Releases | Comments

Researchers now have a faster, surer way to organize and track their highly important cryopreserved samples in a biobank. WHEATON introduces the KeepIT Freezer Box for biobanking applications.


FSH-GEX Receives Trial Approval

May 18, 2011 11:17 am | News | Comments

Glycotope GmbH has recently received approvals to initiate clinical trials for its first glycooptimized non-antibody protein therapeutic FSH-GEX, for in vitro fertilisation and infertility.


Lantheus Announces Imaging Data from Flurpiridaz Study

May 18, 2011 11:08 am | News | Comments

Lantheus Medical Imaging, Inc. announced data from a Phase 2 clinical trial that demonstrated positron emission tomography myocardial perfusion imaging with flurpiridaz F 18 was superior for detecting coronary artery disease.


Tentative Approval for Perrigo ANDA

May 18, 2011 10:54 am | News | Comments

Perrigo Company announced that it has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Levocetirizine Solution, 2.5 mg/5 mL, a generic version of UCB’s Xyzal Oral Solution.


Abbott Diagnostic Gets FDA Clearance

May 18, 2011 10:50 am | News | Comments

Abbott announced that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR test for measuring the viral load of hepatitis C, the leading cause of liver cancer in the United States.


Coffee May Reduce Risk of Lethal Prostate Cancer

May 18, 2011 10:43 am | News | Comments

Men who regularly drink coffee appear to have a lower risk of developing a lethal form of prostate cancer. What's more, the lower risk was evident among men who drank either regular or decaffeinated coffee.


New Treatment Avenue for Breast Cancer

May 18, 2011 10:37 am | News | Comments

Researchers have identified a new avenue for treating breast cancer. In 20 to 30% of breast cancer patients, the over-expression of a particular protein (human epidermal growth factor-2) is the main cause of the proliferation of cancer cells.


Aeterna Zentaris Losses Hit $10.1M

May 18, 2011 10:32 am | News | Comments

Canadian drugmaker Aeterna Zentaris Inc. reported a larger first-quarter loss, as higher expenses canceled out greater sales of its hormone drug Cetrotide. The company said it lost $10.1 million.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.